TY  - GEN
AU  - Mesa,Ruben A
AU  - Kiladjian,Jean-Jacques
AU  - Catalano,John V
AU  - Devos,Timothy
AU  - Egyed,Miklos
AU  - Hellmann,Andrzei
AU  - McLornan,Donal
AU  - Shimoda,Kazuya
AU  - Winton,Elliott F
AU  - Deng,Wei
AU  - Dubowy,Ronald L
AU  - Maltzman,Julia D
AU  - Cervantes,Francisco
AU  - Gotlib,Jason
TI  - SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis
SN  - 1527-7755
PY  - 2017///1211
KW  - Aged
KW  - Benzamides
KW  - administration & dosage
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Janus Kinase Inhibitors
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Nitriles
KW  - Patient Safety
KW  - Primary Myelofibrosis
KW  - drug therapy
KW  - Prognosis
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Retreatment
KW  - Risk Assessment
KW  - Survival Analysis
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1200/JCO.2017.73.4418
ER  -